NASDAQ:FCSC Fibrocell Science (FCSC) Stock Price, News & Analysis → Elon Musk’s Final Masterpiece: “X-9840” (From Paradigm Press) (Ad) Free FCSC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.00▼$3.0050-Day Range$3.00▼$3.0052-Week Range$1.45▼$3.28VolumeN/AAverage Volume78,673 shsMarket Capitalization$29.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Fibrocell Science alerts: Email Address Ad Banyan Hill PublishingAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before June 30 at the very latest. Watch this now to find out why. About Fibrocell Science Stock (NASDAQ:FCSC)Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.Read More Ad Banyan Hill PublishingAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before June 30 at the very latest. Watch this now to find out why. FCSC Stock News HeadlinesFebruary 20, 2024 | forbes.comBest Data Science Bootcamps Online In 2024February 6, 2024 | dailymail.co.ukScience & Tech NewsSeptember 16, 2023 | usnews.comWhat You Need to Know About Becoming a Computer Science MajorApril 7, 2023 | marketwatch.comEpidermolysis Bullosa Therapeutics Market Factual Overview Research Report 2023-2030January 13, 2023 | forbes.comOramed PharmaceuticalsDecember 27, 2022 | thestreet.comFibrocell Science (FCSC) Stock Spikes Following Rare Pediatric Disease Treatment DesignationSee More Headlines Receive FCSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fibrocell Science and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2019Today6/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FCSC CUSIPN/A CIK357097 Webfibrocell.com Phone484-713-6000FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.45) Trailing P/E RatioN/A Forward P/E Ratio30.00 P/E GrowthN/ANet Income$-10,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity23.10% Return on Assets10.56% Debt Debt-to-Equity Ratio0.47 Current Ratio5.09 Quick Ratio5.09 Sales & Book Value Annual Sales$350,000.00 Price / Sales83.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book3.06Miscellaneous Outstanding Shares9,760,000Free FloatN/AMarket Cap$29.28 million OptionableOptionable Beta1.67 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. John Michael Maslowski (Age 44)Pres, CEO & Director Mr. Sean D. Buckley (Age 37)VP of Bus. Admin. & Corp. Sec. Mr. Robert G. PartridgeVP of Global Marketing, Communications and Investor RelationsMs. Michele Mchugh-MazzattaVP of SalesDr. Pierre CompteManaging Director of SwitzerlandKey CompetitorsAmylyx PharmaceuticalsNASDAQ:AMLXKaryopharm TherapeuticsNASDAQ:KPTICitius PharmaceuticalsNASDAQ:CTXRAdicet BioNASDAQ:ACETImmunicNASDAQ:IMUXView All Competitors FCSC Stock Analysis - Frequently Asked Questions How were Fibrocell Science's earnings last quarter? Fibrocell Science Inc (NASDAQ:FCSC) issued its quarterly earnings results on Wednesday, August, 14th. The company reported $1.12 EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $1.30. The business earned $21.79 million during the quarter. When did Fibrocell Science's stock split? Fibrocell Science shares reverse split before market open on Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Fibrocell Science own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fibrocell Science investors own include The Carlyle Group (CG), Celldex Therapeutics (CLDX), Neos Therapeutics (NEOS), Amarin (AMRN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Neurotrope (NTRP), Verastem (VSTM), Synergy Pharmaceuticals (SGYP) and Agile Therapeutics (AGRX). This page (NASDAQ:FCSC) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fibrocell Science Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fibrocell Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.